Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s differentiated obesity drug pipeline and potential for significant upside. Metsera is also viewed as a potential acquisition target for larger biopharma firms looking to enter the obesity market.
Guggenheim rated Metsera a "Buy" with a $56 price target on its ultra-long-acting nutrient-stimulating hormone (NuSH) analog pipeline. The firm sees Metsera’s lead GLP-1 receptor agonist, MET-097i, as a strong contender in the obesity market, with combination potential driving further value. Guggenheim noted that positive data in late 2025 could double the stock’s value over the next 18-24 months.
Bank of America also started with a "Buy" rating and a $38 price objective, emphasizing Metsera’s multi-asset approach in obesity, including both injectable and oral platforms. The firm highlighted five key clinical catalysts expected in 2025 and noted that Metsera’s $640 million cash balance should fund operations through 2026, when Phase 3 trials are anticipated to begin.
Cantor also initiated coverage at "Overweight," pointing to Metsera’s broad obesity pipeline, which it says rivals that of large-cap players. The firm believes Metsera’s lead GLP-1 injectable could demonstrate weight loss efficacy similar to Eli Lilly’s Tirzepatide and sees substantial upside from upcoming clinical readouts in 2025.
Related Articles
Wall Street bullish on Metsera following January IPO on obesity drug pipeline
Tesla, Home Depot lead market cap stock movers on Tuesday
Building permits, new home sales, and oil data to drive markets Wednesday
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。